Carbapenem therapy for bacteremia due to extended-spectrum β-lactamase-producing Escherichia coli or Klebsiella pneumoniae

Diagnostic Microbiology and Infectious Disease

Volumn 70, Issue 1, 2011, Pages 150-153

  Lee, Nan Yao ^a   Huang, Wei Han ^b   Tsui, Ko Chung ^b   Hsueh, Po Ren ^b   Ko, Wen Chien ^a  

^a NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Bacteremia; Carbapenem; ESBL; Escherichia coli; Klebsiella pneumoniae

Indexed keywords

CIPROFLOXACIN; COTRIMOXAZOLE; ERTAPENEM; EXTENDED SPECTRUM BETA LACTAMASE; FLUCONAZOLE; IMIPENEM; LINEZOLID; MEROPENEM; POLYPEPTIDE ANTIBIOTIC AGENT; TIMENTIN;

AGED; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTEREMIA; BACTERIAL METABOLISM; CONTROLLED STUDY; DRUG CHOICE; DRUG EFFICACY; DRUG RESPONSE; DRUG TREATMENT FAILURE; ENZYME SYNTHESIS; ESCHERICHIA COLI; FEMALE; GRAM NEGATIVE SEPSIS; HUMAN; KLEBSIELLA PNEUMONIAE; MAJOR CLINICAL STUDY; MALE; MORTALITY; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SURVIVAL RATE; TREATMENT DURATION;

AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BACTEREMIA; BETA-LACTAMASES; BETA-LACTAMS; CARBAPENEMS; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; FEMALE; HUMANS; IMIPENEM; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; MALE; MIDDLE AGED; THIENAMYCINS; TREATMENT OUTCOME;

EID: 79955028237     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2010.12.008     Document Type: Article

References (15)

1. Andes D.R., Craig W.A. Cephalosporins. Mandell, Douglas, and Bennett's principles and practice of infectious diseases 2005, 294-311. Elsevier/Churchill Livingstone, Philadelphia. 6th ed. G.L. Mandell, J.E. Bennett, R. Dolin (Eds.).
2. Berg M.L., Crank C.W., Philbrick A.H., Hayden M.K. Efficacy of ertapenem for consolidation therapy of extended-spectrum beta-lactamase-producing gram-negative infections: a case series report. Ann Pharmacother 2008, 42:207-212.
3. Chow J.W., Yu V.L. Combination antibiotic therapy versus monotherapy for gram-negative bacteraemia: a commentary. Int J Antimicrob Agents 1999, 11:7-12.
4. Clinical and Laboratory Standards Institute (CLSI) Performance standards for antimicrobial susceptibility testing; 16th informational supplement. (M100-S16) 2006, CLSI, Wayne, PA.
5. DeRyke C.A., Banevicius M.A., Fan H.W., Nicolau D.P. Bactericidal activities of meropenem and ertapenem against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model. Antimicrob Agents Chemother 2007, 51:1481-1486.
6. Jones R.N. In vitro evaluation of ertapenem (MK-0826), a long-acting carbapenem, tested against selected resistant strains. J Chemother 2001, 13:363-376.
7. Kang C.I., Kim S.H., Kim D.M., Park W.B., Lee K.D., Kim H.B., Oh M.D., Kim E.C., Choe K.W. Risk factors for and clinical outcomes of bloodstream infections caused by extended-spectrum beta-lactamase-producing Klebsiella pneumoniae. Infect Control Hosp Epidemiol 2004, 25:860-867.
8. Kang C.I., Kim S.H., Park W.B., Lee K.D., Kim H.B., Kim E.C., Oh M.D., Choe K.W. Bloodstream infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for mortality and treatment outcome, with special emphasis on antimicrobial therapy. Antimicrob Agents Chemother 2004, 48:4574-4581.
9. Kim Y.K., Pai H., Lee H.J., Park S.E., Choi E.H., Kim J., Kim J.H., Kim E.C. Bloodstream infections by extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in children: epidemiology and clinical outcome. Antimicrob Agents Chemother 2002, 46:1481-1491.
10. Paterson D.L., Bonomo R.A. Extended-spectrum beta-lactamases: a clinical update. Clin Microbiol Rev 2005, 18:657-686.
11. Paterson D.L., Ko W.C., Von Gottberg A., Mohapatra S., Casellas J.M., Goossens H., Mulazimoglu L., Trenholme G., Klugman K.P., Bonomo R.A., Rice L.B., Wagener M.M., McCormack J.G., Yu V.L. International prospective study of Klebsiella pneumoniae bacteremia: implications of extended-spectrum beta-lactamase production in nosocomial Infections. Ann Intern Med 2004, 140:26-32.
12. Pitout J.D., Laupland K.B. Extended-spectrum beta-lactamase-producing Enterobacteriaceae: an emerging public-health concern. Lancet Infect Dis 2008, 8:159-166.
13. Teng C.P., Chen H.H., Chan J., Lye D.C. Ertapenem for the treatment of extended-spectrum beta-lactamase-producing Gram-negative bacterial infections. Int J Antimicrob Agents 2007, 30:356-359.
14. Tumbarello M., Sanguinetti M., Montuori E., Trecarichi E.M., Posteraro B., Fiori B., Citton R., D'Inzeo T., Fadda G., Cauda R., Spanu T. Predictors of mortality in patients with bloodstream infections caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae: importance of inadequate initial antimicrobial treatment. Antimicrob Agents Chemother 2007, 51:1987-1994.
15. Yang K., Guglielmo B.J. Diagnosis and treatment of extended-spectrum and AmpC beta-lactamase-producing organisms. Ann Pharmacother 2007, 41:1427-1435.